ABPA SEMINAR
-
Upload
fazlullah-hashmi -
Category
Documents
-
view
64 -
download
5
Transcript of ABPA SEMINAR
![Page 1: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/1.jpg)
ALLERGIC BRONCHOPULMONARY
ASPERGILLOSIS
DR S . FAZLULLAH GUIDED BY
DR D.G. MHAISEKAR SIR
![Page 2: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/2.jpg)
PULMONARY Aspergillosis
• Most common cause A . Fumigatus 80-90 %, then A.flavus, A.terreus, A.niger.
• Microscopic features = High-power photomicrograph can show the
conidiophores with the characteristic head appearance and minute spores.
Medium-power photomicrograph shows septate hyphae branching and angulations.
![Page 3: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/3.jpg)
![Page 4: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/4.jpg)
HYPERSENSITIVITY REACTIONS ALLERGIC BRONCHIAL ASTHMA ABPA BRONCHOCENTRIC GRANULOMATOSIS EXTRINSIC ALLERGIC ALVEOLITIS
SIMPLE COLONIZATION
SAPROPHYTIC GROWTH ASPERGILLOMA INVASIVVE INFECTION IBA CPA IPA
Spectrum of Pulmonary Aspergillosis
![Page 5: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/5.jpg)
IT IS AN IDIOPATHIC INFLAMMATORY LUNG DISEASE CHARACTERIZED BY AN ALLERGIC INFLAMMATORY RESPONSE TO THE COLONIZATION OF ASPERGILLUS OR OTHER FUNGI IN THE LUNG.
ABPA complicates approximately 7 to 14 percent of cases of CHRONIC STEROID–DEPENDENT ASTHMA and 7 to 15 percent of cases of CYSTIC FIBROSIS.
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
![Page 6: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/6.jpg)
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS
ABPA is caused by a Complex Hypersensitivity Reaction to Aspergillus organisms. The fungi proliferate in the airway lumen , producing a constant supply of antigen. Type I hypersensitivity reaction with IgE and
IgG release occurs. TYPE 3 Immune complexes and inflammatory cells are then deposited in the bronchial mucosa. Eosinophilic infiltrates and Necrosis with bronchial wall damage and
bronchiectasis.
![Page 7: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/7.jpg)
![Page 8: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/8.jpg)
CRITERIA for the Diagnosis of ABPA
SEROPOSITIVE ABPA (ABPA-S)
• HISTORY OF Asthma .• ELEVATED TOTAL SERUM IgE • IMMEDIATE SKIN TEST REACTIVITY TO ASPERGILLUS FUMIGATUS• ELEVATED SPECIFIC SERUM IgE TO ASPERGILLUS FUMIGATUS• PRESENCE OF SERUM PRECIPITINS OR ELEVATED SPECIFIC SERUM IGG TO ASPERGILLUS FUMIGATUS
ABPA CENTRAL BRONCHIECTASIS (ABPA-CB)• ABOVE CRITERIA are positive• CENTRAL BRONCHIECTASIS BY HIGH RESOLUTION CT SCAN
![Page 9: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/9.jpg)
CRITERIA for the Diagnosis of ABPA
Other supportive clinical findings• Peripheral Blood Eosinophilia .• CXR = Patchy, Fleeting Infiltrates .• Expectoration of Brown Mucuc
Plugs.• Sputum Culture Positive for
Aspergillus fumigatus.
![Page 10: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/10.jpg)
STAGES OF ABPA
• STAGE 1 ACUTE
• STAGE 2 REMISSION
• STAGE 3 Exacerbation/recurrence
• STAGE 4 Steroid-dependent-asthma
• STAGE 5 Fibrotic lung disease
![Page 11: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/11.jpg)
STAGES Stage I : Acute
• Acute ASTHMA Symptoms
• Elevated SERUM IgE (>1000 IU/ml)
• Peripheral BLOOD EOSINOPHILIA .
• FLEETING INFILTRATES on chest x-ray.
• Positive Specific IgE, IgG Skin Test reactivity, and precipitins to A. fumigatus.
• Responds to STEROIDS/ANTIFUNGAL.
![Page 12: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/12.jpg)
Stage II: Remission• Resolution of symptoms• Resolution of pulmonary infiltrates• Improvement in eosinophilia and A. fumigatus specific blood
abnormalities.
![Page 13: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/13.jpg)
• Recurrence / worsenning of clinical symptoms
• Recurrent pulmonary infiltrates• Rising IgE levels.
Stage III: Exacerbation/recurrence
![Page 14: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/14.jpg)
Stage IV: Steroid-dependent-asthma
• Refractory steriod-dependent asthma.
• Persistently elevated serum IgE levels.
• Persistently elevated A. fumigatus–specific blood abnormalities.
![Page 15: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/15.jpg)
Stage V: Fibrotic lung disease
• Refractory Steriod-dependent asthma• Fibrotic lung disease ( Irreversible
obstructive and restrictive defects with impaired diffusing capacity )
• Chronic bronchiectasis symptoms ( Sputum production, frequent infections)
![Page 16: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/16.jpg)
ABPA Clinical
• Asthma• Bronchial obstruction• Fever, malaise• Expectoration of brownish mucous
plugs• Eosinophilia• Hemoptysis• Wheezing +/-
![Page 17: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/17.jpg)
AREA OF INVOLVEMENT Upper lobes predominate. ACTIVE STAGE - Perihilar ‘infiltrates’ (pseudohilar adenopathy). Massive homogeneous consolidation. Tramline shadows. Toothpaste shadows. Gloved-finger shadows. Air-fluid levels. CHRONIC STAGE - Proximal bronchiectasis manifested by: Parallel line shadows Ring shadows
Radiologic Manifestationsc
![Page 18: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/18.jpg)
TRAMLINE SHADOW
![Page 19: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/19.jpg)
TRAMLINE SHADOW
![Page 20: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/20.jpg)
RING SHADOW
![Page 21: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/21.jpg)
TOOTHPASTE SHADOW
![Page 22: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/22.jpg)
PARALLAL LINE SHADOW
![Page 23: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/23.jpg)
FINGER IN GLOVE Sign
FINGER IN GLOVE SIGN
![Page 24: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/24.jpg)
GLOVED-FINGER SHADOWS
![Page 25: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/25.jpg)
ABPA PFTs
• Airflow obstruction – reduced FEV1.
• Air trapping – increased RV.• Positive BD response in ½
cases.• Mixed Obst. And Rest. If bronchiectasis and fibrosis
present
![Page 26: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/26.jpg)
BRONCHOSCOPY
Plug in airways Airway clear after removal
![Page 27: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/27.jpg)
![Page 28: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/28.jpg)
MUCOID IMPACTION
Without asthma, mucus plug lead to atelectasis. Usually presents with cough.
BRONCHOCENTRIC GRANULOMATOSIS.
Necrotizing granulomas, obstruct and destroy bronchiols . Eosinophilic inflamatory infiltrate and fibrosis with no tissue or vascular invasion.
Syndromes Related to ABPA
![Page 29: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/29.jpg)
EOSINPHILIC PNEUMONITIS
Rarely caused by aspergillus. Cough dyspnea and fever with peripheral pulmonary infiltrate. Diagnosis made by biopsy. Good response to corticosteroids.
HYPERSESITIVITY PNEUMONITIS
Intense repeated inhalation of thermophilic bacteria, fungi, bird excreta, and chemical agents. Causes HYPERSENSITIVITY GRANULOMATOUS INFLAMATION of distal airway .
![Page 30: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/30.jpg)
• ORAL CORTICOSTROIDS = Relief of Bronchospasm , Clearing of pulmonary
infiltrates and decrease IgE levels Dose = 0.5 mg/kg/d for 2 wks then taper. Most patients require prolonged low dose therapy.• ITRACONAZOLE = Low dose (200 mg bid for 16 weeks) can Help in 50% reduction of corticosteroid dose. With no
significant toxicity.
TREATMENT
![Page 31: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/31.jpg)
Saprophytic Aspergillosis (Aspergilloma )
• Fungal hyphae mixed with mucus and cellular debris within a Preexistent Pulmonary Cavity .
• If peripheral, Pleural thickening is characteristic.• Mass is usually seperated from the cavity wall.• Review of 60.000 CXR indentified 0.01 %
Prevelance.• Infection without tissue invasion. • Solid rounded mass, some times mobile
![Page 32: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/32.jpg)
![Page 33: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/33.jpg)
• Clinical findings could be non-specific.• Some patients may remain asymptomatic.• Most frequent symptom is HEMOPTYSIS 75%.• Less commonly chest pain, dyspnea , malaise.• Wheezing and fever (could also be secondary to
underlying disease, or bacterial super infection of the cavity or aspergilloma itself).
Clinical feature
![Page 34: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/34.jpg)
Risk factor Aspergilloma
• The most common predisposing factors are TUBERCULOSIS ( 11% & 17% ) and
SARCOIDOSIS. • Other conditions Bronchogenic Cyst.Pulmonary Sequestration. Pneumocystis Carinii Pneumonia In Patients
With (AIDS) .Bronchiectasis , Ankylosing Spondylitis,
Neoplasm.
![Page 35: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/35.jpg)
Aspergilloma
• Approximately 10% of mycetomas resolve spontaneously.
• Reversibility of the pleural thickening upon resolution of intracavitary fungal material suggests that the thickening of the cavity wall and pleura is due to a Hypersensitivity Reaction.
![Page 36: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/36.jpg)
FUNGUS BALL
![Page 37: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/37.jpg)
MONOD’S SIGN
![Page 38: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/38.jpg)
• Mobile aspergilloma within a pulmonary cystic cavity in a 43-year-old man. Chest CT scans obtained with the patient supine (a) and prone (b) show a change in the position of the aspergilloma. A fumigatus was discovered at bronchoscopy. (Courtesy of Josep M. Mata, MD, Unidad Diagnóstica de Alta Tecnología, Sabadell, Spain.)
![Page 39: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/39.jpg)
Treatment In asymptomatic patients, No therapy needed Surgical Resection = Severe life-threatening hemoptysis Preserved lung funtion. ANTIFUNGAL AGENT = 1. LOCAL Intracavitary
Instillation
AMPHOTERICINE 2. SYSTEMIC ITRACONOZOLE 200 to 400 mg/day
![Page 40: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/40.jpg)
CAVERNOSTOMY.
Selective Bronchial Artery Embolization can be performed in those with
poor lung function.
![Page 41: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/41.jpg)
Semi-invasive (Chronic Necrotizing) Aspergillosis
No vascular invasion. Tissue necrosis and destruction. Granulomatous inflammation similar to that seen in
reactivation tuberculosis. Usually no previous cavity, vs presence of cavity in
non-invasive form. May occur with mild immunosuppression.
![Page 42: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/42.jpg)
Predisposing factors • Chronic debilitating illness, Advanced age. • Alcoholism, Malnutrition.• DM, CF, COPD.• Prolonged steroid therapy, Radiation therapy.• Inactive TB.• Pneumoconiosis.• Sarcoidosis.
Semi-invasive (Chronic Necrotizing) Aspergillosis
![Page 43: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/43.jpg)
SYMPTOMS Often insidious and include chronic cough, sputum
production, fever, and constitutional symptoms. Hemoptysis has been reported in 15% of
affected patients . May manifest with chronic bronchitis and
recurrent episodes of mild hemoptysis.
![Page 44: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/44.jpg)
Invasive Pulmonary Aspergillosis (IPA)
Major risk factors.• Prolonged neutropenia >3 wks or
neutrophil dysfunction.• Corticosteroid therapy .• Transplantation ie BM .• Hematologic malignancy( leukemia)• Cytotoxic therapy.• AIDS.
![Page 45: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/45.jpg)
Airway- Invasive Aspergillosis
• The presence of Aspergillus organisms deep to the airway basement membrane.
• It occurs most commonly in Immunocompromised Neutropenic Patients and In Patients With AIDS.
• Clinical manifestations include acute tracheobronchitis, bronchiolitis, and bronchopneumonia.
![Page 46: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/46.jpg)
• Patients with acute tracheobronchitis usually have normal radiologic findings.
• Occasionally, tracheal or bronchial wall thickening may be seen.
• Bronchiolitis is characterized at HRCT by the presence of Centrilobular Nodules and branching linear or nodular areas of increased attenuation having a "tree-in-bud“ appearance.
Airway- Invasive Aspergillosis
![Page 47: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/47.jpg)
Tree in bud appearance
![Page 48: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/48.jpg)
Characteristic CT findings • Nodules surrounded by a halo of ground-
glass attenuation "HALO SIGN“ or pleura-based, wedge-shaped areas of consolidation.
• These findings correspond to hemorrhagic infarcts.
• In severely neutropenic patients, the halo sign is highly suggestive of angioinvasive aspergillosis.
Angioinvasive Aspergillosis
![Page 49: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/49.jpg)
"HALO SIGN“
Air Crescent sign
![Page 50: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/50.jpg)
• The clinical diagnosis is difficult, and the mortality rate is high.
• Positive culture Methanamine silver, PAS.• BAL 97% specific. But less sensitive.• Chest CT findings = Halo sign, Cresent
sign.• Open or thoracoscopic lung biopsy is
the gold standard.
Diagnosis
![Page 51: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/51.jpg)
Galactomannan Antigen Polysaccharide cell wall component. ELISA test. It has 67-100 % sensitivity and 86-98.8 % specificity. Can precede the clinical diagnosis by 6-14 day.
Diagnosis
![Page 52: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/52.jpg)
Most commonly used medicine - Ampho B 0.6 – 1.2 mg/kg/d , In severly immunocomromized 1 -1.5 mg/kg Response 20-83%.
TREATMENT
![Page 53: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/53.jpg)
Other treatment optionsItraconazol = 200-400 mg/d 39% response. Caspofungin = 50 -70 mg ivVoriconazole, Posaconazole.
TREATMENT
![Page 54: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/54.jpg)
• Voriconazole vs Ampho B, (391 pt randomized ). Succesfull response rate 49.7% for Voriconazole arm, 27.8% for Ampho B. Herbrecht et al, NEM 347: 408 (2002).
• Caspofungin, 70% favorable response in pulmonry disease for salvage therapy, daily dose.
• Vori + Caspo, combination better out come.
TREATMENT
![Page 55: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/55.jpg)
SURGICAL RESECTIONMassive hemoptysis.Localized lesion.
TREATMENT
![Page 56: ABPA SEMINAR](https://reader034.fdocuments.us/reader034/viewer/2022042606/549e2769ac795951768b4635/html5/thumbnails/56.jpg)